Literature DB >> 10098920

Neurocognitive and social functioning in schizophrenia.

J Addington1, D Addington.   

Abstract

This cross-sectional study examined the relationships between neurocognitive and social functioning in a sample of 80 outpatients with DSM-III-R schizophrenia. The neurocognitive battery included measures of verbal ability, verbal memory, visual memory, executive functioning, visual-spatial organization, vigilance, and early information processing. Positive and negative symptoms were assessed with the Positive and Negative Syndrome Scale. A range of social behaviors were assessed using the Social Functioning Scale (SFS), the Quality of Life Scale (QLS), and a video-based test, the Assessment of Interpersonal Problem-Solving Skills (AIPSS). Social functioning as assessed by the SFS was unrelated to neurocognitive functioning. Poor cognitive flexibility was associated with low scores on the QLS and the AIPSS. Verbal ability and verbal memory were also significantly associated with the AIPSS. Visual-spatial ability and vigilance were associated with the sending skills subscale of the AIPSS. In this study, which used a wide range of neurocognitive tests and measures of community functioning and social problem solving, results support earlier research that suggests an association between certain aspects of neurocognitive functioning and social functioning.

Entities:  

Mesh:

Year:  1999        PMID: 10098920     DOI: 10.1093/oxfordjournals.schbul.a033363

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  56 in total

1.  Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits.

Authors:  Joseph Ventura; April D Thames; Rachel C Wood; Lisa H Guzik; Gerhard S Hellemann
Journal:  Schizophr Res       Date:  2010-06-25       Impact factor: 4.939

2.  Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation.

Authors:  Arielle W Tolman; Matthew M Kurtz
Journal:  Schizophr Bull       Date:  2010-07-11       Impact factor: 9.306

3.  Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders.

Authors:  Ronald Bottlender; Anton Strauss; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-22       Impact factor: 5.270

4.  Quality of life and temperament factors in schizophrenia: comparative study of patients, their siblings and controls.

Authors:  Rena Kurs; Herman Farkas; Michael Ritsner
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

5.  Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia.

Authors:  Clare Reeder; Nicola Smedley; Kate Butt; Diana Bogner; Til Wykes
Journal:  Schizophr Bull       Date:  2006-08-10       Impact factor: 9.306

6.  Social/communication skills, cognition, and vocational functioning in schizophrenia.

Authors:  Dwight Dickinson; Alan S Bellack; James M Gold
Journal:  Schizophr Bull       Date:  2006-12-12       Impact factor: 9.306

7.  Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment.

Authors:  Andreas Wittorf; Georg Wiedemann; Gerhard Buchkremer; Stefan Klingberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

8.  Determinants of changes in perceived quality of life in the course of schizophrenia.

Authors:  Michael Ritsner; Anatoly Gibel; Yael Ratner
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

Review 9.  Determinants of functioning and well-being among individuals with schizophrenia: an integrated model.

Authors:  P T Yanos; R H Moos
Journal:  Clin Psychol Rev       Date:  2006-02-09

10.  Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Authors:  Tonmoy Sharma; Catherine Hughes; William Soni; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.